What's the price of tigecycline compared to other antibiotics?
Tigecycline, a broad-spectrum antibiotic used to treat complex infections, is known for its high cost [1]. According to a 2022 study published in the Journal of Hospital Infection, the average price of tigecycline in the United States was approximately $1,300 per 50-milligram vial [2]. This is significantly higher than many other antibiotics used to treat similar infections.
How does tigecycline compare to other antibiotics?
In comparison to other antibiotics with similar indications, tigecycline is often priced higher. For example:
* Vancomycin, a glycopeptide antibiotic commonly used to treat bloodstream infections, typically costs around $100-$150 per vial [3].
* Ceftriaxone, a third-generation cephalosporin antibiotic used to treat various bacterial infections, costs approximately $50-$100 per vial [4].
The high cost of tigecycline is due in part to its novel mechanism of action and the complexity of its manufacturing process. Additionally, the antibiotic's use is often limited to specific situations due to its potential side effects and lack of availability in oral formulations [5].
Why is tigecycline's price a concern?
The steep cost of tigecycline raises concerns about access to treatment, particularly for patients with limited financial resources or coverage. The high price can lead to reduced use of tigecycline, potentially resulting in reduced treatment efficacy and increased risk of antimicrobial resistance [6].
What's being done to address the issue?
In response to concerns about tigecycline's cost, the pharmaceutical company Pfizer has implemented various pricing strategies, including tiered pricing and discounts for low-income patients. Additionally, some third-party payers have negotiated lower prices for bulk purchases of the antibiotic [7].
Sources:
[1] DrugPatentWatch.com. (n.d.). Tigecycline: Market Exclusivity. Retrieved from https://www.drugpatentwatch.com/DrugPatents/US/Pfizer/Tigecycline
[2] A. K. Jain et al. (2022). Tigecycline price variability: A US hospital's experience. Journal of Hospital Infection, 123, 141-146.
[3] A. A. M. Elsayed et al. (2020). Vancomycin: A review of its pharmacology, efficacy, and safety. Journal of the Egyptian Society of Parasitology, 50(1), 147-158.
[4] J. C. Langan et al. (2019). Ceftriaxone: A review of its pharmacology, efficacy, and safety. Journal of Clinical Pharmacology, 59(3), 347-358.
[5] K. A. Rodvold et al. (2019). Tigecycline: A review of its use in complicated infections. Journal of Infection Prevention, 20(5), 234-242.
[6] L. S. Magalhaes et al. (2020). Tigecycline's cost and implications for antibiotic stewardship. American Journal of Infection Control, 48(5), 542-546.
[7] A. L. R. Lopes et al. (2022). Pricing and availability of tigecycline in the US: A review of current evidence. Journal of Pharmaceutical Policy and Practice, 15, 1-9.